{"organizations": [], "uuid": "ec7901adb20a0b8e54a8e8827f61594f2c66fc3b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/22/pr-newswire-alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-juno-therapeutics-inc.html", "country": "US", "domain_rank": 767, "title": "ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc.", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.051, "site_type": "news", "published": "2018-01-22T19:51:00.000+02:00", "replies_count": 0, "uuid": "ec7901adb20a0b8e54a8e8827f61594f2c66fc3b"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/22/pr-newswire-alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-juno-therapeutics-inc.html", "ord_in_thread": 0, "title": "ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc.", "locations": [], "entities": {"persons": [{"name": "ju", "sentiment": "negative"}, {"name": "shane rowley", "sentiment": "none"}], "locations": [{"name": "new york", "sentiment": "none"}, {"name": "esq.", "sentiment": "none"}, {"name": "white plains", "sentiment": "none"}], "organizations": [{"name": "rowley law pllc", "sentiment": "negative"}, {"name": "juno therapeutics, inc", "sentiment": "neutral"}, {"name": "therapeutics, inc.", "sentiment": "none"}, {"name": "juno therapeutics, inc.", "sentiment": "none"}, {"name": "celgene corporation", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Juno Therapeutics, Inc. (NASDAQ: JUNO) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Celgene Corporation. Stockholders will receive $87.00 for each share of Juno Therapeutics, Inc. that they hold. The transaction is valued at approximately $9 billion and is expected to close in the first quarter of 2018.\nIf you are a stockholder of Juno Therapeutics, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/juno . You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com , or by telephone at 914-400-1920 or 844-400-4643 (toll-free).\nRowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com .\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nView original content: http://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-juno-therapeutics-inc-300585948.html\nSOURCE Rowley Law PLLC", "external_links": ["http://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-juno-therapeutics-inc-300585948.html", "http://www.rowleylawpllc.com/investigation/juno", "http://www.rowleylawpllc.com/"], "published": "2018-01-22T19:51:00.000+02:00", "crawled": "2018-01-22T20:12:13.000+02:00", "highlightTitle": ""}